# Lightweight Analysis: MRK, LLY, PFE
**Date:** January 3, 2026

## Executive Summary

Quick comparison of three major pharmaceutical stocks: **Merck (MRK)**, **Eli Lilly (LLY)**, and **Pfizer (PFE)**.

---

## Quick Comparison Table

| Metric | MRK | LLY | PFE |
|--------|-----|-----|-----|
| **Price** | $106.49 | $1,080.36 | $25.17 |
| **Market Cap** | $267.63B | $970.47B | $143.11B |
| **P/E Ratio** | 14.09 | 52.91 | 14.63 |
| **52W Range** | $73.31 - $107.59 | $623.78 - $1,111.99 | $20.92 - $27.69 |
| **Revenue (TTM)** | $64.17B | $45.04B | $63.63B |
| **Net Income Growth** | +45.9% | +102.1% | +276.0% |
| **ROE** | 37.0% | 74.6% | 9.1% |
| **Debt/Equity** | 0.83 | 2.37 | 0.76 |
| **Current Ratio** | 1.36 | 1.15 | 1.17 |

---

## Individual Stock Snapshots

### MRK (Merck) - $106.49
**Valuation:** Attractive (P/E 14.1)
- **Strengths:** Strong fundamentals, solid growth (+45.9% net income), excellent ROE (37%), reasonable debt
- **Technical:** Overbought (RSI 75.6), strong uptrend, near 52W high
- **Outlook:** Well-positioned but extended technically; wait for pullback

### LLY (Eli Lilly) - $1,080.36
**Valuation:** Expensive (P/E 52.9)
- **Strengths:** Exceptional growth (+32% revenue, +102% net income), outstanding ROE (74.6%), GLP-1 momentum
- **Technical:** Overbought (RSI 77.0), strong uptrend but showing bearish MACD divergence, volume declining
- **Outlook:** Premium valuation justified by growth, but overbought; high debt/equity (2.37) is a concern

### PFE (Pfizer) - $25.17
**Valuation:** Attractive (P/E 14.6)
- **Strengths:** Cheap valuation, strong net income growth (+276%), low debt/equity (0.76)
- **Weaknesses:** Low ROE (9.1%), weak revenue growth (+6.8%), post-COVID normalization headwinds
- **Technical:** Neutral RSI (40.3), bearish MACD, uptrend but weak momentum
- **Outlook:** Value play but facing growth challenges; needs pipeline catalysts

---

## Key Insights

### Growth Leaders
1. **LLY** - Dominant growth story with GLP-1 drugs (Mounjaro, Zepbound) driving exceptional revenue and earnings growth
2. **MRK** - Solid growth driven by Keytruda and other oncology products
3. **PFE** - Struggling with post-COVID revenue normalization despite strong bottom-line growth

### Valuation Perspective
- **Value Plays:** MRK and PFE both trade at ~14x P/E, attractive relative to LLY's 53x
- **Growth Premium:** LLY commands premium valuation due to exceptional growth trajectory
- **Best Value:** MRK offers best balance of growth and valuation

### Technical Positioning
- **MRK:** Extended but strong trend; overbought conditions suggest potential pullback
- **LLY:** Overbought with bearish divergence; momentum may be slowing
- **PFE:** Neutral technicals; lacks strong directional momentum

### Risk Factors
- **LLY:** High valuation, elevated debt, overbought technically
- **MRK:** Overbought technically, Keytruda patent cliff concerns (distant)
- **PFE:** Weak revenue growth, pipeline execution risk, post-COVID headwinds

---

## Quick Recommendations

### For Growth Investors
**LLY** - Despite premium valuation, growth trajectory remains strong. Consider on pullbacks below $1,000.

### For Value Investors
**MRK** - Best combination of reasonable valuation, solid growth, and strong fundamentals. Wait for technical pullback to $100-102 range.

### For Contrarian Investors
**PFE** - Deep value play if you believe pipeline can drive growth. High risk/reward; needs catalysts.

---

## Technical Levels to Watch

### MRK
- **Support:** $102 (SMA 20), $96 (SMA 50)
- **Resistance:** $107.59 (52W high)
- **Entry Zone:** $100-102 on pullback

### LLY
- **Support:** $1,047 (SMA 20), $998 (SMA 50)
- **Resistance:** $1,111.99 (52W high)
- **Entry Zone:** $1,000-1,020 on pullback

### PFE
- **Support:** $24.80, $24.48 (SMA 200)
- **Resistance:** $25.78, $27.13
- **Entry Zone:** $24.50-25.00 current range

---

*Analysis generated using FMP API data as of January 3, 2026*


